StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Trimipramine

HCID 5584
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
3564-66-7
Standard-SMILES
CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
InChIKey
ZSCDBOWYZJWBIY-UHFFFAOYSA-N
Summenformel
C20H26N2
Durchschnittliche Molmasse
294,4 g/mol
Monoisotopische Masse
294,20959884

Überblick

Trimipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant. It has a role as an antidepressant, a xenobiotic and an environmental contaminant. It is a dibenzoazepine and a tertiary amino compound. It is functionally related to an imipramine.

Namen und Bezeichner

Bevorzugter Name
Trimipramine
IUPAC
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
Englischer Name
Trimeproprimin
Summenformel
C20H26N2
Molmasse
294.43

Namen und Synonyme

trimipramine739-71-9TrimeprimineTrimeproprimineSapilentbeta-MethylimipramineTrimepriminaTrimipraminaTrimipraminum7162 RPIL 6001IL-6001
Weitere Namen anzeigen
10645RPSurmontylBrn 1321466Trimeproprimin5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,β-trimethyl-, (-)-5H-Dibenz(B,F)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)- (9ci)5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-, (-)- (8CI)
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amineRP-71625-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine6S082C9NDT5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine7162-RP10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine

Datenbank-Bezeichner

CAS

Eigenschaften

Berechnete Struktureigenschaften

XLogP
5,8
Polarare Oberfläche (TPSA)
6,5 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
4
Schwere Atome
22
Formalladung
0
Komplexität
317

Experimentelle und physikochemische Eigenschaften

Drugs · 3 Einträge

DEA NFLIS-Drug Category -> Antidepressants

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

LogP4.2
Solubility · 2 Einträge

Slightly soluble

2.60e-02 g/L

Human Drugs · 3 Einträge

Antidepressants -> Tricyclic antidepressants (TCA)

Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Tricyclic

Pharmaceuticals

Melting Point45 °C
Physical DescriptionSolid
Dissociation Constants · 3 Einträge

9.24

9.24

8.5

Collision Cross Section · 3 Einträge

170.5 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: Antidepressants]

169.17 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (97.8%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P272, P273, P280, P301+P316, P302+P352, P304+P340, P305+P354+P338, P317, P319, P321, P330, P332+P317, P333+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 46 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

REACH registered substance: Trimipramine (EC: 212-008-3)

Trimipramine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazard Classes and CategoriesAcute Tox. 3 (97.8%)

Toxikologische Informationen

Treatment · 1 Eintrag

Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. (L1712)

HepatotoxicityIn clinical trials, liver test abnormalities were uncommon in patients taking trimipramine (

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

Protein Binding93%-96% (to plasma proteins)
Pharmacodynamics · 1 Eintrag

Trimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.

Mechanism of ActionTrimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Biological Half-Life11-18 hrs
Metabolism/Metabolites · 2 Einträge

Hepatic

Hepatic Half Life: 11-18 hrs

FDA Pharmacological Classification · 6 Einträge

6S082C9NDT

TRIMIPRAMINE

Established Pharmacologic Class [EPC] - Tricyclic Antidepressant

Trimipramine is a Tricyclic Antidepressant.

TRIMIPRAMINE

Tricyclic Antidepressant [EPC]

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
3564-66-7、3564-75-8、739-71-9
PubChem CID
5584
DTXSID
DTXSID8023715
ChEMBL
CHEMBL644
ChEBI
CHEBI:9738
UNII
6S082C9NDT、9K5931C1H5、QJ9MUH57H8
EC Number
212-008-3
Nikkaji
J53.921J、J6.960D、J86.105G

171.2 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physikochemische Eigenschaften

Siedepunkt
411.8 · 411.8±44.0 °C(Predicted)
Dichte
1.029 · 1.029±0.06 g/cm3(Predicted)
pka
9.38 · 9.38±0.28(Predicted)
Exposure RoutesOral. Rapid absorption
Toxicity SummaryTrimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Signs and Symptoms · 1 Eintrag

Side effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Trimipramine

1.2

4.9

Maintenance therapy is in the range of 50 to 150 mg/day trimipramine maleate.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 50 mg/day, Lowest Therapeutic Dose (LTD): 0.6 mg/kg-day, and Screening Dose: 0.0002 mg/kg-day.

30-Jul-20

MeSH Pharmacological Classification · 2 Einträge

Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Absorption, Distribution and ExcretionRapid absorption
Cellular LocationsMembrane

Verwendung und Herstellung

Uses · 2 Einträge

Use (kg) in Switzerland (2009): >750

For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance

Use Classification · 2 Einträge

Pharmaceuticals

Pharmaceuticals -> Nervous System -> Antidepressants